Libyan Multiple Sclerosis Registry Study

NCT ID: NCT07264725

Last Updated: 2025-12-04

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 369 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-08-02
• Study Completion Date: 2025-04-30

Brief Summary

This study aims to understand differences in access to diagnosis and treatment for people with multiple sclerosis (MS) receiving care in Libya. The study uses data from the Libyan Multiple Sclerosis Registry, which collects clinical and treatment information from patients at two tertiary neurology centres. The main focus is to examine how long it takes for patients to receive an MS diagnosis, who has access to high-efficacy disease-modifying therapies, and how these factors relate to disability levels. The results will help identify gaps in MS care within a conflict-affected health system and guide improvements in services for patients in Libya.

Conditions

Multiple Sclerosis

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Interventions

Disease-Modifying Therapies

This is an observational study. No medications are assigned, administered, or modified by the study team. Disease-modifying therapies (DMTs) are recorded only as exposure variables based on routine clinical care. All drugs listed in this record are prescribed independently by treating neurologists as part of standard care, and the study does not influence treatment decisions in any way.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adults aged 18 years or older
• Diagnosis of multiple sclerosis according to the 2017 McDonald criteria
• Receiving care at Tripoli University Hospital or Omar Askar Hospital
• Able to provide written informed consent
• Recorded EDSS score at registry entry
• Availability of core demographic and diagnostic information

Exclusion Criteria

• Clinically isolated syndrome (CIS)
• Age younger than 18 years
• Absence of confirmed multiple sclerosis diagnosis
• Missing key clinical variables required for primary analysis (EDSS, phenotype, or DMT information)
• Declined or unable to provide informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Zintan

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Tripoli University Hospital

Zintan, , Libya

Countries

Libya

Other Identifiers

ZFM/2024/MS-03

Identifier Type: REGISTRY

Identifier Source: secondary_id

ZFM-2024-MS03

Identifier Type: -

Identifier Source: org_study_id